Myriad Prostate Cancer Testing

Genetic testing reveals what you can’t see but really want to know about prostate cancer, allowing patients and providers to make the best treatment decisions.

Myriad Prostate Cancer Testing

Genetic testing reveals what you can’t see but really want to know about prostate cancer, allowing patients and providers to make the best treatment decisions.

Learn how genetic testing can provide better answers for the best prostate cancer treatment in our FREE Patient Testing Guide.

Learn how genetic testing can provide better answers for the best prostate cancer treatment in our FREE Patient Testing Guide.

Prolaris®

Prostate cancer prognostic test

Prostate cancer is personal and treatment should be too. Prolaris is for any untreated man with prostate cancer and helps patients and providers answer pressing clinical questions like:

  • Are you safe for active surveillance or do you need treatment?
  • Is your cancer at risk of spreading?
  • What are your chances of surviving prostate cancer?
  • Can you benefit from hormone therapy (ADT)?

I’m a patient

I’m a provider

Hereditary cancer testing

You may have inherited more than just your eye color from your parents.

MyRisk is a genetic test that identifies mutations to determine if you have an inherited form of cancer. MyRisk helps qualify patients for new, personalized treatments – like targeted therapies and understand if you are at risk of developing a secondary cancer.

I’m a patient

I’m a provider

Meet Myriad UroSuite

The complete suite of tests for a full prostate cancer workup

Myriad’s UroSuite gives health care providers the ability to directly order a complete suite of tests for comprehensive insights to guide prostate cancer treatment, including: 

  • Prolaris® Prostate Cancer Prognostic Test
  • MyRisk® Hereditary Cancer Test
  • Precise Tumor

Myriad Genetics is the only lab to offer comprehensive testing across the spectrum of prostate cancer care, along with best-in-class support and specialists for you and your patients at every step. 

Meet Myriad UroSuite

The complete suite of tests for a full prostate cancer workup

Myriad’s UroSuite gives health care providers the ability to directly order a complete suite of tests for comprehensive insights to guide prostate cancer treatment, including: 

  • Prolaris® Prostate Cancer Prognostic Test
  • MyRisk® Hereditary Cancer Test
  • Precise Tumor

Myriad Genetics is the only lab to offer comprehensive testing across the spectrum of prostate cancer care, along with best-in-class support and specialists for you and your patients at every step. 

Genetic insights that guide cancer treatment through every step of the journey

  • for newly diagnosed and untreated patients

    Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to determine if a patient can safely watch their cancer in favor of active surveillance or if they should pursue treatment.

  • for patients with a family history of cancer and/or advanced disease

    MyRisk is a germline test that offers a multi-gene panel to determine a patient’s risk of developing secondary cancers, as well as their children’s risk for the same germline mutations. MyRisk can also qualify patients for newer, personalized treatments such as targeted therapies and immunotherapy.

  • for advanced patients

    A somatic test that assesses 500+ genes, as well as key biomarkers like MSI, TMB and PD-L1, to determine if a patient’s tumor may be appropriate for novel therapies or clinical trials.

Previous Test
    Next Test

    Affordable genetic testing

    Excellent insurance coverage

    100% Medicare coverage for qualified patients

    Affordable

    93% of patients pay $0

    Financial assistance

    If you receive a bill and your expected out-of-pocket cost exceeds your budget, we have ways to help.

    News and announcements

    0

    Provider Perspective: How to choose the right tool for precision prostate cancer care

    While urologists and radiation oncologists are increasingly turning to genetic testing for prostate cancer management, many are still relying on traditional tools…

    0

    Understanding Prostate Cancer: A Guide for Men and Their Loved Ones

    Prostate cancer is a very common disease, roughly 1 in 8 American men will be diagnosed with prostate cancer during their lifetime. Receiving a prostate…

    0

    Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

    SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN) a leader …